Related Experiment Videos
A future for neonatal alpha1-antitrypsin screening?
1Department of Paediatrics and Psychiatry, University of Lund, University Hospital, Malmö, Sweden.
Insights
Neonatal screening for alpha1-antitrypsin deficiency (alpha1ATD) is recommended by the WHO. Early detection aids in managing liver disease and preventing emphysema, though debates continue on optimal screening timing and potential disadvantages.
Area of Science:
- Medical genetics
- Public health screening
- Pulmonology
Background:
- Alpha1-antitrypsin deficiency (alpha1ATD) is a genetic disorder with varying prevalence, posing risks for liver disease in infancy and emphysema in adulthood.
- Smoking significantly exacerbates alpha1ATD, reducing life expectancy and prolonging the asymptomatic phase.
Purpose of the Study:
- To evaluate the benefits and drawbacks of neonatal screening for alpha1-antitrypsin deficiency (alpha1ATD).
- To discuss the optimal timing for alpha1ATD screening, considering early diagnosis versus adolescent-onset risks like smoking.
Main Methods:
- Review of existing alpha1ATD screening programs, including the Swedish experience.
- Analysis of potential advantages and disadvantages of neonatal versus school-age screening for alpha1ATD.
- Consideration of psychosocial impacts and ethical concerns related to alpha1ATD screening.
Main Results:
- Neonatal screening allows for early diagnosis and treatment of liver disease and informed genetic counseling regarding smoking risks.
- School-age screening (11-12 years) aligns with the age when smoking initiation may occur, allowing for child participation in screening decisions.
- Potential disadvantages include psychosocial reactions in mothers and discrimination risks, with uncertainties regarding screening participation and anti-smoking advice efficacy.
Conclusions:
- The optimal timing for alpha1-antitrypsin deficiency screening remains a subject of ongoing debate, balancing early intervention benefits against potential psychosocial and discrimination risks.
- Evidence from the Swedish program suggests that early information and advice can deter smoking in adolescents with alpha1ATD.
- Further research is needed to address uncertainties regarding voluntary screening participation, psychosocial outcomes, and the effectiveness of anti-smoking interventions at different ages.
Abstract:
A WHO expert group recommends neonatal screening for alpha1-antitrypsin deficiency (alpha1ATD). Homozygous alpha1ATD PiZZ occurs in 1 in 5,000 of the U.S. Caucasian population and up to 1 in 500 individuals of the European population, with a large regional variation. It is a risk factor that predisposes mainly to liver disease in early infancy and emphysema in early adulthood. Most importantly, smoking decreases the duration of the asymptomatic phase and life expectancy by 10-20 y. The Swedish alpha1AT screening programme and subsequent information and advice prevented the majority of adolescents from starting to smoke. The involved parents and alpha1ATD adolescents retrospectively recommended neonatal screening. Potential advantages of neonatal alpha1AT screening are: early diagnosis and treatment of neonatal liver disease, optimal treatment of fever and bacterial infections theoretically preventing liver cell damage, genetic advice and information about the consequences of passive and active smoking. Potential advantages of postponing screening until age 11-12 y are: identification of alpha1ATD close to the age when smoking may start, and possibility for the child to take part in the screening decision. Disadvantages of alpha1AT screening are: psychosocial reactions-the mother probably being most vulnerable in the neonatal period-and discrimination by insurance companies and employers. Important uncertainties are: lack of knowledge concerning participation in a voluntary alpha1AT screening, psychosocial reactions and the efficacy of anti-smoking advice if the information is given to school-age children and families. Thus the question whether and when to screen for alpha1ATD is still the topic of lively debate.